Expansion of AESARA Europe with the Appointment of Market Access Expert, Sameera Tak
AESARA (www.aesara.com) is pleased to announce the appointment of experienced industry market access executive Sameera Tak, MSc, to the European Strategic Partnerships team.
Sameera joins AESARA bringing over 16 years’ experience in the innovative biotech and pharmaceutical industry. Sameera will cover clinical operations and supply chain as well as AESARA’s core service area of value & access strategy and operations. She brings a differentiated breadth of experience as well as depth of expertise to her consulting role as a peer thought partner to industry clients.
Based in the Zug, Switzerland, biotech hub, Sameera will also take on the Geschäftsführerin or operational board director role, running AESARA Europe’s newly established Swiss operations.
Gavin Outteridge, Managing Director of AESARA Europe said, “We’re delighted to appoint Sameera to this role, where her strategic access insight and history of operational delivery can combine for client success, as well as AESARA’s ambitious growth agenda. I’ve known Sameera as a client of my own, and her values displayed over many years absolutely align with AESARA’s Trusted – Bold – Transformative trifecta.”
Ruslan Horblyuk, Global Head of AESARA Strategic Partnerships added: “I am thrilled to welcome Sameera to AESARA and look forward to working alongside her in bringing AESARA’s 'Change Before Change' mindset to our European life sciences partners.”
“I am very excited and at the same time truly humbled to be a part of AESARA’s growth phase. I am looking forward to becoming a trusted and transformative partner for AESARA’s life sciences innovator clients,” said Sameera Tak.
About AESARA
AESARA is a market access agency with a focused purpose to impact healthcare decision-making to improve people’s lives. Established in 2016, we are a woman and minority-owned company with biopharma seasoned industry professionals in the U.S., Canada, and Europe. Our diverse team is passionate about delivering to our client’s transformative market access strategies and innovative digital communication solutions. For more information, please visit www.aesara.com and connect with AESARA on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005166/en/
Contact information
Pam Read
+1 587 233 4260 / pam@aesara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member10.5.2024 18:45:00 EEST | Press release
EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Pejvack Motlagh MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. “We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience. The appointment of Dr Motlagh is critical for Egle, as the company is moving to clinical development of assets in oncology and auto-immunity. Pejvack will impact the future development of the rich pipeline at Egle, based on the modulation of regulatory T cells. As we advance toward the clinical development of EGL-001, John’s expertise in business development in the field of oncology is instrumental for us to successfully execute on our strategic priorities.” said Vincent Brichard, M.D., EGLE’s Interim CEO and Board member. “I am excited to join Egle Therapeutics to translate into the c
HighRadius Named 2024 Gartner® Magic Quadrant™ Leader for the Third Time in a Row10.5.2024 17:00:00 EEST | Press release
HighRadius, the leading provider of the Autonomous Finance Platform for the office of the CFO, has once again been named a Leader in the 2024 Gartner Magic Quadrant for Invoice-to-Cash Applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240510668572/en/ HighRadius Named 2024 Gartner® Magic Quadrant™ Leader for the Third Time in a Row (Graphic: Business Wire) Gartner Magic Quadrant gives enterprise technology shoppers an unbiased assessment of how well-competing providers are performing against Gartner’s market view and is supplemented by validated user reviews. According to Gartner, “Leaders execute well against their current vision and are well positioned for tomorrow.” This is the third consecutive year for HighRadius to be placed as a leader on the report. “We're honored to be recognized for our maniacal focus on invoice-to-cash business outcome improvements - DSO, Bad Debt, Interchange Fees, & Productivity,” sai
The Ministry of Investment of Saudi Arabia (MISA) Signs MoU with Ant International to Expand Business in Saudi Arabia, Supporting Regional Digital Innovation10.5.2024 16:36:00 EEST | Press release
The Ministry of Investment of Saudi Arabia (MISA) has signed a Memorandum of Understanding (MoU) with Ant International, to facilitate the business expansion into the Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507130337/en/ (Photo: Business Wire) Ant International’s President, Douglas Feagin, met with Mr. Eng Saleh Khabti, Deputy Minister of Investment of Saudi Arabia during a signing ceremony held in Riyadh, to welcome the new partnership and sign an agreement outlining shared goals for technological innovation and economic growth opportunities in Saudi Arabia. Through this partnership, MISA welcomes and supports Ant International’s expansion plan to establish an entity in Saudi Arabia, enabling assistance when acquiring licences and certificates to expand and enhance its service offerings. Ant International will use Saudi Arabia as a key gateway into the Middle East to further expand the reach of its paymen
Wipro Appoints Vinay Firake as Chief Executive Officer for APMEA Strategic Market Unit10.5.2024 16:11:00 EEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Vinay Firake as the Chief Executive Officer, APMEA (Asia Pacific, India, Middle East & Africa) Strategic Market Unit (SMU), effective immediately. Vinay will report to Srini Pallia and will also join the Wipro Executive Board. Vinay has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Senior Vice President and Managing Director of Wipro-Nordics Business Unit based in Stockholm, where he led Operations across all industries and services. Prior to that, he led the Manufacturing & Automotive Business Unit in Europe and held various roles spanning Europe and North America, including Global Head for the Enterprise Digital Operations & Platforms business and Sales Head for Wipro's Enterprise Applications businesses in Europe. “Vinay has successfully led Wipro in diverse regio
Kolmar BNH, a Top-Tier Korean Enterprise Specializing in the Production of HemoHIM, Dedicates over 2% of its Annual Sales to R&D10.5.2024 16:00:00 EEST | Press release
Kolmar BNH (KOSDAQ: 200130), a manufacturer of HemoHIM, a health-enhancing functional food, has emerged as a frontrunner in the global Original Development Manufacturing (ODM) market, owing to its pioneering investments in research and development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240510895890/en/ A researcher from Kolmar BNH Health Food Lab. (Photo: Kolmar BNH) Founded in 2005, Kolmar BNH is an ODM company for health-functional food products. ODM enterprises, encompassing various sectors from trend analysis to R&D, product conceptualization, manufacturing, and quality assurance, cater to customers with entrepreneurial aspirations. This framework facilitates opportunities for individuals with a passion for business and ideas. The cornerstone of Kolmar BNH's competitiveness lies in its technological adeptness, underpinned by substantial R&D investments. The company annually allocates over 2% of its sales revenue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom